CAS RN: 68291-97-4 | Product Number: Z0026
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
|Appearance||White to Almost white powder to crystal|
|Purity(HPLC)||min. 98.0 area%|
|Purity(with Total Nitrogen)||min. 98.0 %|
|Melting point||163.0 to 167.0 °C|
|Melting Point||165 °C|
|Hazard Statements||H302 : Harmful if swallowed.
H361 : Suspected of damaging fertility or the unborn child.
H336 : May cause drowsiness or dizziness.
|Precautionary Statements||P261 : Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
P304 + P340 + P312 : IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial
Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex
Effects of zonisamide on dopaminergic system
The clinical pharmacokinetics of the newer antiepileptic drugs: Focus on topiramate, zonisamide and tiagabine
Therapeutic drug monitoring of the newer antiepileptic drugs
Safety Data Sheet (SDS) Search
The requested SDS is not available.
Please check that the Product Number you have entered is correct.
If your information is correct and you are still not able to view the requested SDS, please Contact Us for more information.